High Proportion of Death due to Smoking- Growth of O2 Concentrator at 5.3% in Europe: Actual Market Research

Comparatively, as per WHO reports, the European region has one of the highest death proportions attributing to smoking. It is estimated to be responsible for 16% of all deaths in over 30, whereas globally, it is an average of 12%. A smoker’s lungs experience inflammation which causes wheezing and short of breath. Years of irritation can give the lungs a hard time doing their work on their own and thus need external support for breathing. The research report titled Europe Medical Oxygen Concentrators Market Outlook, 2026 by Actual Market Research categorizes the market to forecast the revenues and analyze the trends in each of the following segments: based on product, technology, end users, countries & major companies.

Out of the 20 countries that smoke the most cigarettes, 15 of them are entirely or partially in Europe. The Europe market for oxygen concentrators was led by Germany, which along with the UK and France accounted for half of the market share. These aggressive smoking behaviors in the region have indirectly lead a road for the oxygen concentrator market in the region to grow over a value of USD 0.47 Billion in the year 2015. The key regional players are Invacare Corporations, Philips Health Care, AirSep Corporation, DeVilbiss Healthcare, Nidek Medical Products, Inc., Inogen, Inc., Inova Labs, Inc., O2 Concepts & others.

A significant increase in the number of people opting for oxygen therapy is expected to incline in the region. The population of 50 to 75 age demography, who in their early age were frequent smokers, is likely to develop emphysema and other choric issues. The oxygen cylinder segment held to a market of little less than 50% in 2020, leading the Europe market, based on the product type. The ongoing technological advancements in portable oxygen concentrators will accelerate product adoption at an anticipated CAGR of 8% over the forecasted period. In Europe, it is estimated that over 85% of the people who undergo oxygen therapy are once smokers.

The novel coronavirus can cause significant respiratory distress and the majority of the patients who do die are a result of extreme respiratory failure. The oxygen concentrators are being used in the treatment of Covid-19 cases as a replacement of the respiratory device ventilator. Pointing to excessive wastage of oxygen, the continuous slow technology in Europe had a growth rate restricted at 4%, while the pulse flow technology is expected to cover over a quarter share of the market. However, the high cost of the device is likely to hamper the growth of the market during the forecast period.

Thirty out of every 100 European adults smoke every day and one of every ten adult smokers will die from tobacco smoking; a higher ratio of 1:15 is found in Eastern Europe. The region has COPD, lung cancer, and pneumonia as the three leading contributors to respiratory mortality in Europe. In 2020, the nonhome care segment including hospitals, ambulatory surgical centers, and & physician offices was valued to higher than 44% of the total market. With increasing affordability in the region, home health care has gained enough popularity in the region. The demand for oxygen concentrators from the home care segment is expected to grow over a market rate of 7% through the forecasted period.